SciBase Secures Funding, Expands Collaboration Amidst Margin Pressure
Event summary
- SciBase reported a 45% increase in net sales for the full year 2025 (TSEK 40,461), with a 57% increase when adjusted for currency effects.
- The company incurred a loss after tax of TSEK 87,063 in 2025, and negative cash flow from operations of TSEK 84,578.
- SciBase completed a rights issue of approximately SEK 83 million and saw 96.4% subscription rates.
- The company received FDA approval for extended labeling in the US and its Nevisense technology was included in US NCCN Guidelines for Melanoma.
The big picture
SciBase's rapid revenue growth is being offset by substantial losses and negative cash flow, necessitating the recent capital raise. The company's reliance on partnerships like Castle Biosciences and regulatory approvals like the FDA expansion highlight the risks associated with its growth strategy. The rights issue provides a short-term lifeline, but sustained profitability will depend on operational efficiencies and successful market penetration.
What we're watching
- Margin Resilience
- The gross margin decline, attributed to currency effects, gold prices, and production investments, warrants close monitoring to determine if these pressures are transitory or indicative of a longer-term trend impacting profitability.
- Castle Partnership
- The expanded collaboration and loan agreement with Castle Biosciences represents a significant dependency; the success of their joint clinical studies will be crucial for SciBase's future revenue and market penetration.
- US Adoption
- While US sales showed strong growth, the pace at which Nevisense adoption expands within the US market, particularly beyond the NCCN guidelines inclusion, will dictate the sustainability of this momentum.
Related topics